Rationale: Menopause is associated with changes in sex hormones, which affect immunity, inflammation, and osteoporosis and may impair lung function. Lung function decline has not previously been investigated in relation to menopause.
The nonreproductive phase of a woman's life begins with menopause (1) . Cessation of menstruations may be accompanied by lack of energy; hot flushes; vaginal discharge; insomnia; osteoporosis; and an increased risk of developing chronic conditions, such as diabetes and cardiovascular disease (2) (3) (4) (5) (6) . Menopause is associated with profound changes in the activity of the hypothalamo-pituitarygonadal axis: as 17b-estradiol production in the ovaries ceases, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations rise (7, 8) . Low levels of 17b-estradiol are associated with increased systemic inflammation and inflammation in the lungs (9) (10) (11) (12) (13) (14) (15) (16) . The inflammation markers C-reactive protein and IL-6 are inversely associated with FVC and FEV 1 (17, 18) . These findings point toward a possible association between menopause and increased lung function decline. Given today's life expectancy far beyond the age of menopause, understanding how to maintain good health and quality of life in later years is important (1, (19) (20) (21) (22) . The role of sex hormones in respiratory health is increasingly acknowledged (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) . However, potential changes in respiratory health as related to reproductive aging in women are still poorly understood (23, 33, 34) .
A recent longitudinal analysis of a large population based survey showed higher incidence of new-onset asthma and increase in respiratory symptoms as related to menopause (28) . Potential changes in lung function with menopause have only been addressed in cross-sectional analyses. One population-based study of women aged 45 to 55 years, not using hormonereplacement therapy, found lower lung function in post-menopausal women compared with women who still had regular menstruations (27) . A recent study from the UK Biobank found an association between cessation of menstruation and lower lung function, whereas another study saw no independent effect of menopause on FVC and FEV 1 levels (35, 36) . It has been reported that lifestyle factors, such as smoking, may be more detrimental after menopause, whereas some hormonereplacement therapy regimens seem to be associated with higher lung function in post-menopausal women (37) (38) (39) . Whether obesity impacts on respiratory health in menopause is not known, although sex hormones and body fat mass are interrelated (40, 41) and effect modification of body mass index (BMI) on the role of hormone-replacement therapy is suggested in cross-sectional studies (42) . The aim of the present study was to investigate the association of menopausal status with decline in lung function over a 20-year period, using data from a large European, population-based cohort. Some of the results of this study have been previously reported in the form of an abstract to the European Respiratory Society annual congress (43) .
Methods

Study Population
The European Community Respiratory Health Survey (ECRHS) is an international multicenter study including three waves: ECRHS 1 in 1991-1994, ECRHS 2 in 1998-2002, and ECRHS 3 in 2010-2012 (described in detail at http://www.ecrhs. org). The age range at baseline was 25-48 years and the median (range) observation time for women participating in all three waves was 19.7 (17.9-22.4) years. The present study includes 19 centers in Europe (see Table E1 in the online supplement). The examinations included an interviewerled questionnaire, spirometry, and serum sampling. At ECRHS 2 and 3 women additionally answered standardized questionnaires on women's health. For 2,484 women, serum samples from ECRHS 2 and/or 3 were analyzed for FSH and LH (see online supplement). Inclusion criteria are presented in Figure 1 . Ethical approval was obtained from the appropriate ethics committee and each participant provided informed written consent.
Classification according to Menopausal Status
Every woman contributed with up to three observations (ECRHS 1, 2, and/or 3; Author Contributions: K.T., principal author, conception and design of the work, acquisition, analysis and interpretation of data, drafting the work, and revising for important intellectual content. B.M. and A.J., interpretation of data and revising for important intellectual content. S.S. and S.H., acquisition, analysis and interpretation of data, and revising for important intellectual content. L.P., analysis and interpretation of data and revising for important intellectual content. B.B., P.D., S.C.D., K.A.F., J.G.A., J.A.G.B., J.H., M.H., D.J., R.J., E.L., J.M.M.R., N.M.A., I.P., N.P.-H., C.R., J.L.S.-R., V.S., J.S., and C.S., conception and design of the work, acquisition and interpretation of data, and revising for important intellectual content. B.L. and F.G.R., conception and design of the work, acquisition, analysis and interpretation of data, drafting the work, and revising for important intellectual content. ORIGINAL ARTICLE number of observations [n obs ] = 3,295). We attributed each observation separately to a menopausal status, at the same time as the pulmonary function tests were conducted. At baseline we included only nonmenopausal women, excluding women who retrospectively reported their last period more than 1 year before baseline. To determine menopausal status at ECRHS 2 and 3 we performed latent class analysis to identify subgroups within our population, based on menopause-related factors, such as hormone levels and presence and/or regularity of menstruations (44, 45) . Latent class analysis is commonly used in medical research to classify subjects by selected characteristics (.2,000 publications listed on www.PubMed.gov). The number of classes was restricted to three, retrospectively labeled: (1) nonmenopausal, (2) transitional, and (3) post-menopausal. Observations were assigned classmemberships based on response probabilities (see Table E2 ). The algorithm, grouping the most similar observations, was repeated 30 times with a maximum of 10,000 iterations. The included categorical variables were FSH in quintiles, LH in quintiles, and menstrual status as reported by participants (see Table  E2 ). Each participant was present either in one, two, or all three classes, representing the reproductive stage at different waves.
Outcomes
FVC and FEV 1 were recorded following standardized methods (46, 47) . The spirometers that were used are presented in Table E1 .
Statistical Analysis
Data of all three waves were modeled by linear mixed effects models, allowing for random intercepts (48) . By including spirometric measurements and an interaction term of the menopausal status with age, we determined the lung function decline defined as the slope of change in lung capacity, which can be interpreted as the mean annual decline (ml/yr) associated with each menopausal status. We adjusted for fixed effects of age, weight, pack-years, current smoking, and type of spirometer at each wave, as well as height at baseline and age at completed full-time education as a socioeconomic proxy, which if missing (6.0%) was imputed as the population mean. Missing age (3.8%) and weight (9.4%) were included as age and weight at a different wave plus the mean increase during follow-up. The participant's identification number, nested in the respective study center, was accounted for as random effect. Stratified analyses were performed among never-smokers, eversmokers, and BMI categories according to the World Health Organization. To investigate whether results were driven by a history of asthma, or gynecologic disorders, such as polycystic ovary syndrome, endometriosis, surgical menopause (reported at ECRHS 2 or 3), or premature menopause (,40 yr), we performed sensitivity analysis within the respective subgroups without these conditions. We further tested potential heterogeneity between study centers and an alternative model, accounting for change in height over the study period. Analyses were performed using R version 3.1.0 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Characteristics of the subjects at baseline are presented in Table 1 . The class conditional probabilities and standard errors for the class membership, determined by latent class analysis, can be found in Table E2 .
The included 1,438 women provided a total of 3,295 complete observations (pulmonary function tests) including data on menopausal status and covariates (up to three observations per woman). The nonmenopausal class included 60% (n obs = 1,992), the transitional class 18% (n obs = 583), and the postmenopausal class 22% (n obs = 720) of the observations. The mean age was 39 years in the nonmenopausal, 53 years in the transitional, and 56 years in the postmenopausal class (Table 2 ). Weight and BMI were highest in the transitional class (Table 2) . Figures 2 and 3 show the best linear unbiased predictions for FVC and FEV 1 of the whole population, obtained by adding Eligible women participating in ECRHS 1, 2, and 3 with available hormone data n = 2,484
Women not taking exogenous hormones n = 1,959
Women without non-menopause-related irregular menstruation n = 1,852
Women being nonmenopausal at ECRHS 1 n = 1,793
Aged 25 years or older at ECRHS 1 n = 1,586
Available spirometry data with delta FVC < 100 ml/yr n = 1,532
Women with complete information* n = 1,438 Definition of abbreviations: BMI = body mass index; PFT = pulmonary function test. *N total = 1,438; baseline observations for 69 women were incomplete and therefore excluded (follow-up observations of these women were included). † Annualized change over follow-up.
together the population predictions (based on the fixed effects estimates) and the estimated contributions of the random effects (48) . Both curves show a negative increase in slope when a large proportion of women enter the transitional or menopausal stage.
The mean age dependent lung function decline for all groups was 215.9 ml/yr (95% confidence interval [CI], 218.2 to 213.6) for FVC and 224.0 ml/yr (95% CI, 225.9 to 222.0) for FEV 1 . The interaction term of menopausal status with age showed that the mean FVC decline was additionally increased by 210.2 ml/yr (95% CI, 213.1 to 27.2) for women classified as transitional and 212.5 ml/yr (216.2 to 28.9) for women classified as post-menopausal, compared with women menstruating regularly. The mean FEV 1 decline additionally increased by 23.8 ml/yr (95% CI, 26.3 to 22.9) for women classified as transitional and by 25.2 ml/yr (95% CI, 28.3 to 22.0) for women classified as post-menopausal.
Current smoking was significantly associated with FEV 1 decline (229.3 ml; 95% CI, 254.0 to 24.7) compared with former smoking and lifelong nonsmoking, whereas pack-years were significantly associated with both FEV 1 decline (22.3 ml/pack-year; 95% CI, 23.0 to 21.5) and FVC decline (21.0 ml/pack-year; 95% CI, 21.9 to 20.1). The results for other covariates of the primary analysis are presented in Tables E3 and E4. Analysis of FVC decline as related to menopause and stratified according to BMI at ECRHS 3 showed a higher age-related decline (Figure 4) and indicated a smaller menopause-related decline with increasing BMI (P interaction , 0.01 for transitional women and P interaction , 0.001 for postmenopausal women) ( Figure 5 ). Eversmokers indicated a higher age-related decline and higher menopause-related decline than never-smokers. For FEV 1 we observed a similar but less distinct pattern (Figures 4 and 5) .
The sensitivity analysis showed that the results were not driven by a history of asthma, by gynecologic disorders, by hypertension or cardiovascular disorders, or by surgical or premature menopause (data not given). Results were consistent for individual centers with sufficient participants (Galdakao, Albacete, Grenoble, Paris, Reykjavik, Bergen, Umeå, and Uppsala).
Height changed over the study period. The alternative model accounting for change in height showed a 25% reduced, yet still significant, decline in FVC for both the transitional (27.7 ml/yr; 95% CI, 210.6 to 24.7) and the post-menopausal class (29.0 ml/yr; 95% CI, 212.7 to 25.5), compared with the nonmenopausal class. The decline for FEV 1 was reduced by approximately 50% and not significant after such adjustment (transitional class: 22.1 ml/yr; 95% CI, 24.7 to 0.3) (post-menopausal class: 22.6 ml/yr; 95% CI, 25.8 to 0.5).
Discussion
This population-based study of 1,438 women aged 25-48 years from nine European countries over 20 years with repeated spirometry, hormone measurements, and questionnaire data found that lung function declined more rapidly in women who were transitional or post-menopausal, as compared with women who were nonmenopausal. To our knowledge, this is the first longitudinal 
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population-based study that investigates lung function decline in relation to menopause. The menopause-related decline was more pronounced for FVC than for FEV 1 , which points toward a restrictive rather than an obstructive pattern. Stratified analyses and sensitivity analyses revealed that these findings were very robust. Effect modification by BMI seems plausible, because circulating androgens are converted to estrogens in adipose tissue. Ever-smokers show a suggested steeper decline in both age and menopause-related impairment of lung function, possibly because of a combined effect of smoking on the lungs and its antiestrogenic effects. Sensitivity analyses in women without a history of asthma, surgical menopause, or gynecologic disorders showed similar and statistically significant results.
We used latent class analysis to define the menopausal status rather than fixed cutoffs, because this type of analysis accounts better for the underlying biology and the information gathered from the participants. Clustering of the most similar observations forms the latent classes, and the multivariate and repetitive nature of the classification process allows for a dynamic grouping based on maximum likelihood criteria. We restricted classification to three classes because the data favored more classes by a marginally better fit, yet it supported a structure of two clearly defined classes (nonmenopausal and post-menopausal), and a more heterogeneous class representing different stages within the menopausal transition. The transitional class might include a minority of postmenopausal and nonmenopausal women. Hormone levels of women older than 60 years who were still categorized as transitional are on average lower than in women categorized as post-menopausal. The trajectories of FSH over the menopausal transition are not uniform across the population (e.g., women with a higher BMI or expressed sexuality are more likely to show a slower increase and lower post-menopausal level of FSH) (49) (50) (51) . These women are most likely postmenopausal; however, hormonally they are more similar to the transitional class, as determined by the latent class analysis (7, 8) . The heterogeneity of the transitional class might dilute associations slightly.
Hormonal changes in menopause, linked to complex biologic events might contribute to the demonstrated acceleration in lung function decline with menopause. One possible mechanism is systemic inflammation, which is associated with menopausal hypoestrogenism and impaired lung function. The way 17b-estradiol affects inflammation depends strongly on the type of inflammatory or immunogenic stimulus, the involved cell types, the target organ's specific microenvironment, and metabolism, leading to different antiinflammatory and proinflammatory effects (10, 52) . Animal models suggest that low levels of 17b-estradiol might amplify inflammation and higher levels might attenuate it (11, 12) . In rats and mice, surgically induced menopause enhances pleural exudation, leukocyte migration, and lung myeloperoxidase activity among others (13, 14) . Ovariectomy is further associated with increased levels of inflammatory markers, which decreased after 17b-estradiol substitution (13, 14) . A comprehensive review concluded that in all available inflammatory models of the lung, 17b-estradiol was demonstrated to have an antiinflammatory effect (10) .
Furthermore, hypoestrogenism plays a critical role in osteoporosis, which results in reduced height of the thoracic vertebrae, which may mechanically reduce the expansion of the thoracic cage during inspiration and place the diaphragm in a suboptimal position (53, 54) . Our findings suggested that the accelerated decline related to menopause was in part explained by osteoporosis, because accounting for change in height attenuated the associations of menopause with decline in FVC and FEV 1 .
Strengths of the present study are the availability of repeatedly measured lung function and hormone measurements and interview/questionnaire data for large population samples. A unique window of opportunity was taken advantage of, because the study subjects were aged 25-48 years at baseline and most women went through the age of the menopausal transition during the 20-year follow-up. Hormone measurements at two time points are a major strength of this analysis, and the use of latent class analyses to define menopause based on both hormone measurement and questionnaire information. The crude definition of menopause at baseline, only based on questionnaire data, is a weakness of the study that may have introduced minor nondifferential error and thus attenuated true results. The outcomes of the study, objectively measured lung function parameters, are a strength and spirometric measurement error is unlikely to be related to menopausal status. The change in spirometers between surveys is accounted for in the analyses; however, it is possible that a residual nondifferential measurement error may have attenuated the true results. The multinational and multicentric design of the study allows for high external validity and the consistency across geographic and cultural borders suggests biologic explanatory mechanism rather than confounding by sociocultural factors.
Conclusions
The present study shows that menopause was associated with an accelerated decline in lung function, beyond the expected age-related decline. This was most pronounced for FVC. The results were consistent across subgroups and independent of smoking history. The effect size for FEV 1 was comparable with smoking 20 cigarettes per day for 2 years, and for FVC to smoking 20 cigarettes per day for 10 years. The mechanisms underlying the associations between reproductive aging and respiratory health need to be further investigated. Future studies should address potential beneficial effects of hormone-replacement therapy. The results from the present study should be taken into account, because they are highly relevant for the health and quality of life of a large and steadily increasing number of women. n ORIGINAL ARTICLE
